We believe therapeutic neurogenesis and neuroprotection can revolutionize the treatment of several currently incurable neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and Huntington's disease.

NeuroNova uses its integrated platform of drug discovery technologies, the Neurogenesis Qualifier, to identify novel drug targets and existing drugs that can stimulate the formation of new neurons in the brain.

NeuroNova has two drug candidates in clinical development for Parkinson’s disease and ALS, and further promising compounds in discovery and preclinical development.

NeuroNova intends to out-license its drug candidates or partner them with pharmaceutical or biotechnology companies at clinical development stage. In some cases, NeuroNova may retain full rights to market a product in specific countries.

Founded in 1998 by two leading neuroscientists from the Karolinska Institute, NeuroNova is based in Stockholm, Sweden, and employs 14 full-time staff. NeuroNova is financed by the Swedish venture capital companies HealthCap and Investor Growth Capital.